@alnylam.com
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
Icon
JPEG
About
Description
Alnylam Pharmaceuticals is a leading brand that utilizes Nobel Prize-winning science to pioneer the field of RNA interference (RNAi) and develop groundbreaking medicines. With a vision to revolutionize the lives of individuals suffering from diseases with limited treatment options, Alnylam was founded in 2002 by esteemed leaders in the life sciences industry. They have successfully introduced the world's first and only approved RNAi therapeutics, including ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and AMVUTTRA® (vutrisiran).
Alnylam focuses on four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases. Their RNAi-based medicines work by targeting the root genetic cause of diseases, distinguishing them from other classes of medications. This approach silences or disables disease-causing genes, providing innovative and effective treatments.
The name Alnylam is derived from the constellation Orion's belt's central star, Alnilam, which symbolizes the brand's passion for discovery. Alnylam Pharmaceuticals is committed to harnessing the potential of RNAi therapeutics and leading the way in transforming the future of medicine
Company Type
Public Company
Company Size
1001-5000
Year Founded
2002
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online